Olivier Boyer
Olivier Boyer is an expert in Immunology at Hôpital Charles-Nicolle (France) (France). Olivier Boyer has authored 284 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 907 (community average: 125). How the SLR is computed.
LeadR Profile
Immunology
Subspecialties: Hematology - Rheumatology - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 284
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Cohort study of 23 patients with seropositive immune-mediated necrotizing myopathy. PMID 42562677 — muscular diseases, autoantibodies, muscles, internal medicine, cohort studies, diagnosis | Rev Med Interne | 2026 | 0 |
| Anti-carbamylated fibrinogen autoantibodies of IgG and IgA isotypes contribute to a better prognostic stratification in very early rheumatoid arthritis: data from the French national ESPOIR cohort. PMID 42504150 — autoantibodies, antibodies, arthritis, rheumatic diseases, immunoglobulin a, fibrinogen, prevalence, arthritis, rheumatoid, therapeutics, smoking | Arthritis Rheumatol | 2026 | 0 |
| Cellular and Cytokine Responses of Corneal Fibroblasts Exposed to Keratopigmentation Inks in Vitro. PMID 42480955 — cytokines, vascular endothelial growth factor a, solvents, ophthalmology, macrophages, corneal neovascularization, phagocytosis, fibroblasts, ink | Exp Eye Res | 2026 | 0 |
| Tocilizumab for severe and refractory mucous membrane pemphigoid. PMID 42200380 — cytokines, sexually transmitted diseases, serum, skin diseases, pemphigoid, bullous, proteomics, mucous membrane, membranes | J Eur Acad Dermatol Venereol | 2026 | 0 |
| Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading. PMID 41821311 — cells, genes, epitopes, nanoparticles, transgenes, liver, capsid, immunity, endothelial cells, therapeutics | Mol Ther | 2026 | 0 |
Clinical Studies 9
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase IIa Trial of Anti CD19 CAR T Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy NCT07493395 — skin, cells, sclerosis, pharmaceutical preparations, leukapheresis, drug therapy, receptors, antigen, lymph, receptors, chimeric antigen, therapeutics, immunosuppression therapy, infusions, intravenous, t-lymphocytes, scleroderma, systemic, chemotherapy, car-t cell | Phase 2 | Active not recruiting | 2026 |
LeadR Networks
Main global connection map